![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 22, 2024 4:14:25 PM
https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx
It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.
Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM